Premium
Drug Development and the FDA's Critical Path Initiative
Author(s) -
Woosley RL,
Cossman J
Publication year - 2007
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/sj.clpt.6100014
Subject(s) - clinical pharmacology , drug development , pharmaceutical industry , medicine , drug , warning signs , pharmacology , intensive care medicine , clinical research , engineering ethics , engineering , transport engineering
Advances in biomedical research over recent decades have substantially raised expectations that the pharmaceutical industry will generate increasing numbers of safe and effective therapies. However, there are warning signs of serious limitations in the industry's ability to effectively translate biomedical research into marketed new therapies. Clinical pharmacologists should be aware of these signals and their potential impact. Here, we discuss a strategy, where clinical pharmacology can play an important role to improve the process of drug development. Clinical Pharmacology & Therapeutics (2007) 81 , 129–133. doi: 10.1038/sj.clpt.6100014